Citations

Clear

2303 citation(s) found for "Yu, Edward".

Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology
Mohler, James L. , Antonarakis, Emmanuel S. , Armstrong, Andrew J. , D’Amico, Anthony V. , Dorff, Tanya B. , Eastham, James A., Enke, Charles A. , Farrington, Thomas A., Higano, Celestia S. , Horwitz, Eric M. , Kuettel, Michael, McKenney, Jesse K. , Netto, George J. , Penson, David F. , Pow‐Sang, Julio M. , Pugh, Thomas J., Richey, Sylvia, Roach, Mack , Rosenfeld, Stan, Schaeffer, Edward M. , Shabsigh, Ahmad , Spratt, Daniel E. , Srinivas, Sandy, Tward, Jonathan D. , Shead, Dorothy A. , Freedman-Cass, Deborah A., Antonarakis, Emmanuel S. , Davis, Brian J. , Spratt, Daniel E , Antonarakis, Emmanuel S , Armstrong, Andrew J , Antonarakis, Emmanuel S , Hurwitz, Michael E. , Ippolito, Joseph E. , Kane, Christopher J. , Lang, Joshua M. , Plimack, Elizabeth R. , Small, Eric J.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | May 22, 2019 | Volume: 17 | Issue: 5 | Pages: 479-505

10.6004/jnccn.2019.0023 | PMID 31085757 Get It

The NCCN Guidelines for Prostate Cancer include recommendations regarding diagnosis, risk stratification and workup, treatment options for localized disease, and management of recurrent and advanced disease for clinicians who treat patients with prostate cancer. The portions of the guidelines included herein focus on the roles of germline and somatic genetic testing, risk stratification with nomograms and tumor multigene molecular testing, androgen deprivation therapy, secondary hormonal therapy, chemotherapy, and immunotherapy in patients with prostate cancer.
A Critical Assessment of the Linear No-Threshold Hypothesis
Siegel, Jeffry A. , Brooks, Antone L., Zanzonico, Pat , Doss, Mohan , O’Connor, Michael K. , Silberstein, Edward B., Welsh, James S. , Greenspan, Bennett S. , OʼConnor, Michael K, Fisher, Darrell R.

Mayo Clinic

Clinical Nuclear Medicine | May 20, 2019 | Volume: 44 | Issue: 7 | Pages: 521-525

10.1097/rlu.0000000000002613 | PMID 31107746 Get It

Abstract The Society of Nuclear Medicine and Molecular Imaging convened a task group to examine the evidence for the risk of carcinogenesis from low-dose radiation exposure and to assess evidence in the scientific literature related to the overall validity of the linear no-threshold (LNT) hypothesis and its applicability for use in risk assessment and radiation protection. In the low-dose and dose-rate region, the group concluded that the LNT hypothesis is invalid as it is not supported by the available scientific evidence and, instead, is actually refuted by published epidemiology and radiation biology. The task group concluded that the evidence does not support the use of LNT either for risk assessment or radiation protection in the low-dose and dose-rate region.
Quality Improvement Goals for Acute Kidney Injury
Kashani, Kianoush , Rosner, Mitchell H. , Lewington, Andrew , O’Donoghue, Dónal , Wilson, F. Perry , Nadim, Mitra K. , Silver, Samuel A. , Zarbock, Alexander , Ostermann, Marlies , Mehta, Ravindra L. , Kane‐Gill, Sandra L. , Pickkers, Peter , Bihorac, Azra , Siew, Edward D. , Frazee, Erin N. , Macedo, Etienne , Kellum, John A. , Tolwani, Ashita , Ronco, Claudio , Juncos, Luis A. , Rewa, Oleksa , Bagshaw, Sean M. , Mottes, Theresa , Liu, Kathleen D. , Heung, Michael , Wu, Vin‐Cent , Rewa, Oleksa G. , Wilson, F Perry , Mehta, Ravindra L , Ding, Xiaoqiang , Frazee, Erin N , Macedo, Etienne , Ronco, Claudio , Wu, Vin-Cent , Kane-Gill, Sandra L , Kashani, Kianoush B , Kellum, John A , Silver, Samuel A , Haase, Michael , Palevsky, Paul M. , Koyner, Jay L. , Forni, Lui G. , Bihorac, Azra , Bagshaw, Sean M , Juncos, Luis A , Ostermann, Marlies , Rewa, Oleksa G , Siew, Edward D

Mayo Clinic

Clinical Journal of the American Society of Nephrology | May 17, 2019 | Volume: 14 | Issue: 6 | Pages: 941-953

10.2215/cjn.01250119 | PMID 31101671 Get It

AKI is a global concern with a high incidence among patients across acute care settings. AKI is associated with significant clinical consequences and increased health care costs. Preventive measures, as well as rapid identification of AKI, have been shown to improve outcomes in small studies. Providing high-quality care for patients with AKI or those at risk of AKI occurs across a continuum that starts at the community level and continues in the emergency department, hospital setting, and after discharge from inpatient care. Improving the quality of care provided to these patients, plausibly mitigating the cost of care and improving short- and long-term outcomes, are goals that have not been universally achieved. Therefore, understanding how the management of AKI may be amenable to quality improvement programs is needed. Recognizing this gap in knowledge, the 22nd Acute Disease Quality Initiative meeting was convened to discuss the evidence, provide recommendations, and highlight future directions for AKI-related quality measures and care processes. Using a modified Delphi process, an international group of experts including physicians, a nurse practitioner, and pharmacists provided a framework for current and future quality improvement projects in the area of AKI. Where possible, best practices in the prevention, identification, and care of the patient with AKI were identified and highlighted. This article provides a summary of the key messages and recommendations of the group, with an aim to equip and encourage health care providers to establish quality care delivery for patients with AKI and to measure key quality indicators.
Abstract LB-242: Aberrant crypt foci (ACF) are not surrogate biomarkers of sporadic adenoma prevention with celecoxib: Results from the Adenoma Prevention with Celecoxib (APC) trial
Cho, Nancy L. , Redston, Mark , Carothers, Adelaide M., Wilton, Andrew S. , Sontag, Stephen J. , Nishioka, Norman S., Giardiello, Frances, Saltzman, John R. , Gostout, Chris, Eagle, Craig, Hawk, Ernest T. , Zauber, Ann Graham , Hornick, Jason L. , Bertagnolli, Monica M.

Mayo Clinic

Cancer Research | May 11, 2019 | Volume: 68 | Issue: 9_Supplement | Pages: LB-242-LB-242

10.1158/1538-7445.am2008-lb-242 Get It

Abstract Aberrant crypt foci (ACF) are the earliest visible neoplastic lesions in the colorectum. The natural history of these lesions and their role in the adenoma-carcinoma sequence are unknown. We studied ACF in a subset of patients enrolled in the Adenoma Prevention with Celecoxib (APC) Trial to determine whether the presence of ACF in the rectum correlated with that of adenomas in the entire large intestine. Participants were randomized to placebo (n=17), celecoxib 200 mg bid (n=15), or celecoxib 400 mg bid (n=13). Magnification chromoendoscopy (MCE) was performed to identify and biopsy ACF within the rectum at baseline and after 8-12 months of medication use. A total of 670 ACF were identified in 45 patients, and 70 of these were examined histologically. All of the ACF examined were non-dysplastic. Analysis showed no differences in ACF number between baseline and post-treatment studies (8.3±1.0 vs. 6.3±1.1) and no modulation by treatment (celecoxib vs placebo; p=0.77). Immunohistochemical studies showed that ACF contained cells exhibiting increased proliferation, but lacked other features of neoplasia such as increased Cox-2 expression and microvascular density, nuclear localization of β-catenin, or decreased expression of the tumor suppressors SMAD4, estrogen receptor (ERα) or MGMT. Of the secondary markers assessed at baseline, only SMAD4 expression correlated with post-treatment adenoma recurrence. Taken together, these data showed that non-dysplastic ACF are not accurate surrogate endpoint biomarkers of colorectal adenoma risk or NSAID chemoprevention response.
U.S.-Based National Surveillance for Fidaxomicin Susceptibility of Clostridioides difficile-Associated Diarrheal Isolates from 2013 to 2016
Thorpe, Cheleste M. , McDermott, L. A., Tran, Midori , Chang, Justin , Jenkins, Stephen G., Patel, Robin , Forbes, Betty A., Johnson, Stuart , Gerding, Dale N. , Patel, Robin , Snydman, D R , Goldstein, E. J. C. , Snydman, David R.

Mayo Clinic

Antimicrobial Agents and Chemotherapy | May 10, 2019 | Volume: 63 | Issue: 7 | Pages: No page available

10.1128/aac.00391-19 | PMID 31085514 Get It

In 2011, we initiated a sentinel surveillance network to assess changes in Clostridioides (formerly Clostridium ) difficile antimicrobial susceptibility to fidaxomicin from 6 geographically dispersed medical centers in the United States. This report summarizes data from 2013 to 2016. C. difficile isolates or toxin-positive stools from patients were referred to a central laboratory. Antimicrobial susceptibility was determined by agar dilution. CLSI, EUCAST, or FDA breakpoints were used, where applicable.
OR29-4 Pregnancy Outcomes in Women with Pheochromocytoma and Paraganglioma: An International Multi-Center Study
Bandgar, Tushar , Bausch, Birke, Ariza, Nicole Iniguez, Kaur, Ravinder Jeet , Pereira, Maria Fernanda Bádue , Neumann, Hartmut P.H., Bancos, Irina , Hudiakova, N. V. , Ariza, Nicole Marie Iniguez, Young, William John , Eng, Charis

Mayo Clinic

Journal of the Endocrine Society | May 10, 2019 | Volume: 3 | Issue: Supplement_1 | Pages: No page available

10.1210/js.2019-or29-4 Get It

The Unified Airway: Does Asthma Influence Paranasal Sinus Pneumatization?
Marino, Michael J. , Riley, Charles A. , Wu, Eric , Weinstein, Jacqueline E. , McCoul, Edward D.

Mayo Clinic

Ear, Nose & Throat Journal | May 8, 2019 | Volume: 99 | Issue: 2 | Pages: 89-93

10.1177/0145561319848992 | PMID 31064242 Get It

Asthma has been implicated as a driving force in lower airway remodeling; however, its effect on upper airway development has not been studied. Clinical disease, particularly cystic fibrosis (CF), has been associated with anatomical paranasal sinus variation, although the mechanism for these variations remains unclear. The purpose of this study was to determine whether asthma is associated with altered sinus pneumatization. Five hundred ninety-one computed tomography scans, including 303 adolescents (age 13-18) and 288 adults (age > 18), were evaluated using the Assessment of Pneumatization of the Paranasal Sinuses (APPS) instrument. The APPS score is validated for assessing anatomical variation and total sinus volume. A diagnosis of asthma was ascertained from the medical record, and patients with CF were included as a positive control group. Patients with asthma had mean APPS score of 9.66, compared to 9.85 for participants without asthma ( P = .585). Subgroup analysis demonstrated similar findings among adults ( P = .817) and adolescents ( P = .585). Patients with a diagnosis of CF had significant sinus hypoplasia according to a mean APPS scores of 3.50 ( P < .001). Sinus hypoplasia persisted in both adults ( P < .001) and adolescents ( P < .001) with CF. The presence of asthma is not associated with altered paranasal sinus pneumatization. In contrast, CF is associated with significantly reduced sinus pneumatization. These findings suggest that aberrant sinus pneumatization may not be a feature of asthma and that chronic mucosal respiratory disease is not a generalizable cause for altered paranasal sinus pneumatization.
Changes in Vedolizumab Utilization Across US Academic Centers and Community Practice Are Associated With Improved Effectiveness and Disease Outcomes
Koliani‐Pace, Jenna L., Singh, Siddharth , Luo, Michelle , Hirten, Robert , Kochhar, Gursimran , Chang, Shannon, Lukin, Dana J. , Gao, Youran, Bohm, Matthew , Shmidt, Eugenia , Meserve, Joseph , Winters, Adam C. , Chablaney, Shreya , Yang, Jiao, Huang, Zhongwen, Boland, Brigid S. , Shashi, Preeti , Weiss, Aaron , Varma, Sashidhar, Fischer, Monika , Sultan, Keith , Shen, Bo , Kane, Sunanda V. , Loftus, Edward V. , Sandborn, William J. , Lasch, Karen, Dulai, Parambir S. , Aniwan, Satimai , Loftus, Edward V , Chang, Shannon, Swaminath, Arun C. , Gupta, Nitin Kumar , Faleck, David M. , Weiss, Aaron, Hudesman, David , Sands, Bruce E , Colombel, Jean‐Frédéric , Siegel, Corey A

Mayo Clinic

Inflammatory Bowel Diseases | May 3, 2019 | Volume: 25 | Issue: 11 | Pages: 1854-1861

10.1093/ibd/izz071 | PMID 31050734 Get It

Abstract Background Vedolizumab effectiveness estimates immediately after Food and Drug Administration (FDA) approval for ulcerative colitis (UC) and Crohn’s disease (CD) are limited by use in refractory populations. We aimed to compare treatment patterns and outcomes of vedolizumab in 2 time frames after FDA approval. Methods We used 2 data sets for time trend analysis, an academic multicenter vedolizumab consortium (VICTORY) and the Truven MarketScan database, and 2 time periods, May 2014–June 2015 (Era 1) and July 2015–June 2017 (Era 2). VICTORY cumulative 12-month clinical remission, corticosteroid-free remission, and mucosal healing rates, and Truven 12-month hospitalization and surgery rates, were compared between Eras 1 and 2 using time-to-event analyses. Results A total of 3661 vedolizumab-treated patients were included (n = 1087 VICTORY, n = 2574 Truven). In both cohorts, CD and UC patients treated during Era 2 were more likely to be biologic naïve. Compared with Era 1, Era 2 CD patients in the VICTORY consortium had higher rates of clinical remission (31% vs 40%, P = 0.03) and mucosal healing (42% vs 58%, P < 0.01). These trends were not observed for UC. In the Truven database, UC patients treated during Era 2 had lower rates of inflammatory bowel disease–related hospitalization (22.4% vs 9.6%, P < 0.001) and surgery (17.2% vs 9.4%, P = 0.008), which was not observed for CD. Conclusion Since FDA approval, remission and mucosal healing rates have increased for vedolizumab-treated CD patients, and vedolizumab-treated UC patients have had fewer hospitalizations and surgeries. This is likely due to differences between patient populations treated immediately after drug approval and those treated later.